Claims for Patent: 4,689,320

Summary for Patent: 4,689,320

Title:	Method for inhibiting propagation of virus and anti-viral agent
Abstract:	Described is a method for inhibiting propagation of virus which comprises delivering one or more oligodeoxynucleotides or polydeoxynucleotides to a place where a messenger RNA (mRNA) generated on propagation of the virus exists, characterized in that the oligodeoxynucleotides or polydeoxynucleotides are identical in DNA sequence with a portion of the structure of DNA hybridizable to the mRNA, the structure being capable of hybridizing to the mRNA. Also described is an anti-viral agent which comprises an effective amount of one or more oligodeoxynucleotides or polydeoxynucleotides with a conventional liquid vehicle or excipient, characterized in that the oligodeoxynucleotides or polydeoxynucleotides are identical in DNA sequence with a portion of the structure of DNA hybridizable to an mRNA generated on propagation of the virus, the structure being capable of hybridizing to the mRNA. The method and the agent can widely be applied to the treatment of viral diseases.
Inventor(s):	Kaji; Akira (Higashikurume-shi, Tokyo, JP)
Assignee:
Application Number:	06/661,204
Patent Claims:	1. A pharmaceutical composition, consisting essentially of an effective antiviral amount of an oligodeoxynucleotide or polydeoxynucleotide which has a sequence which is identical to a portion of DNA which is hybridizable to messenger RNA of herpes virus, said oligodeoxynucleotide or polydeoxynucleotide being capable of hybridizing to said messenger RNA; and a pharmaceutically acceptable carrier. 2. The composition of claim 1, wherein said virus is herpes simplex virus. 3. The composition of claim 1, wherein said virus is herpes simplex virus-1. 4. The composition of claim 1, wherein said oligodeoxynucleotide or polydeoxynucleotide is capable of hybridizing immediate early messenger RNA of herpes simplex virus. 5. The composition of claim 1, wherein said oligodeoxynucleotide or polydeoxynucleotide can hybridize with a non-structural gene of said herpes virus. 6. The composition of claim 5, wherein said non-structural gene is ICP 4. 7. The composition of claim 1, wherein said oligodeoxynucleotide or polydeoxynucleotide has the sequence 3'-CGC.AGC.CTC.TTG.TTC.GTC.GC-5'. 8. The composition of claim 1, wherein said oligodeoxynucleotide or polydeoxynucleotide has the sequence 3'-GCA.CCC.GGG.ACC.TTT.ACC.GC-5'. 9. The composition of claim 1, in the form of an injectable solution. 10. The composition of claim 1, in the form of a topical preparation. 11. The composition of claim 1, in the form of an eye drop solution. 12. The composition of claim 1, which includes a mixture of said oligodeoxynucleotides or polydeoxynucleotides. 13. A method for treating herpes virus infections which comprises applying to a subject an effective antiviral amount of a pharmaceutical composition consisting essentially of an effective antiviral amount of an oligonucleotide or polydeoxynucleotide which has a sequence which is identical to a portion of DNA which has a hybridizable to messenger RNA of herpes virus, said oligodeoxynucleotide or polydeoxynucleotide being capable of hybridizing to said messenger RNA; and a pharmaceutically acceptable carrier. 14. The method of claim 13, wherein said composition is topically applied to said subject. 15. The method of claim 13, wherein said composition is applied to an eye of said subject. 16. The method of claim 13, wherein said composition is injected into said subject. 17. The method of claim 13, wherein said composition is administered to said subject at a dose of from 1-20000 .mu.g/kg/day. 18. The method of claim 13, wherein said virus is herpes simplex virus. 19. The method of claim 13, wherein said virus is herpes simplex virus-1. 20. The method of claim 13, wherein said oligodeoxynucleotide or polydeoxynucleotide is minus strand DNA. 21. The method of claim 13, wherein said oligodeoxynucleotide or polydeoxynucleotide has the sequence 3'-CGC.AGC.CTC.TTG.TTC.GTC.GC-5'. 22. A method for treating a virus infection which comprises applying to a subject an effective antiviral amount of a pharmaceutical composition consisting essentially of an effective antiviral amount of an oligodeoxynucleotide or polydeoxynucleotide which has a sequence which is identical to a portion of DNA which is hybridizable to messenger RNA of a virus selected from the group consisting of adeno virus, vaccinia virus, influenza virus, rhino virus and polio virus, said oligodeoxynucleotide or polydeoxynucleotide being capable of hybridizing to said messenger RNA and a pharmaceutically acceptable carrier or diluent.